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PURPOSE. Retinopathy of prematurity (ROP) is a vision-threatening complication of a
premature birth, in which the etiology still remains unclear. Importantly, the molecular
processes that govern these effects can be investigated in a perturbed plasma proteome
composition. Thus, plasma proteomics may add new insights into a better understanding of
the pathogenesis of this disease.
METHODS. The cord and peripheral blood of neonates (30 weeks gestational age) was drawn
at birth and at the 36th postmenstrual week (PMA), respectively. Blood samples were
retrospectively subdivided into ROP(þ) and ROP() groups, according to the development of
ROP.
RESULTS. The quantitative analysis of plasma proteome at both time points revealed 30 protein
abundance changes between ROP(þ) and ROP() groups. After standardization to gestational
age, children who developed ROP were characterized by an increased C3 complement
component and fibrinogen level at both analyzed time points.
CONCLUSIONS. Higher levels of the complement C3 component and fibrinogen, present in the
cord blood and persistent to 36 PMA, may indicate a chronic low-grade systemic inflammation
and hypercoagulable state that may play a role in the development of ROP.
Keywords: retinopathy of prematurity, proteome, complement, fibrinogen
Retinopathy of prematurity (ROP) is a biphasic ocular diseaseoccurring primarily in infants delivered before approxi-
mately 28 weeks gestational age with immature retina.1 It
includes a delayed physiologic retinal blood vessels develop-
ment, followed by anarchic vessel proliferation and a potential
for succeeding retinal detachment.2 An initial vessel loss may
evoke ischemic events with detrimental effects on neuronal
homeostasis and functions.3 Although early detection and
treatment often result in a full recovery, severe cases may lead
to long-lasting problems of reduced visual acuity, high myopia,
strabismus, nystagmus, glaucoma, late retinal detachments, or
even blindness.4–8 Until now, the pathogenesis of ROP has not
been completely understood. The various ROP risk factors
include low gestational age and low birthweight, higher or
fluctuating oxygen levels during oxygen therapy, hyperglyce-
mia, insulin use, inadequate postnatal nutrition, improper
insulin-like growth factor 1 concentration, poor postnatal
growth, pre- and postnatal infection, and genetic factors.9
However, we still know too little about why some infants
develop this complication of prematurity while others, born at
the same age and with similar clinical characteristics, do not.
Studies on protein abundance profiling may not only broaden
our knowledge about potential achievable biomarkers and help
enhance our understanding of the molecular process driving
ROP but also explain the susceptibility of some preterm
newborns to ROP. Up to now, limited research has identified
several proteins (i.e., these from the insulin-like growth factor
pathway, mitochondrial superoxide dismutase, and chordin-like
protein 1), in which altered levels in plasma were related to the
increased risk of ROP.10,11 A study dealing with vitreous
samples of children with ROP has also revealed some proteins
potentially involved in the pathomechanism of ROP.12 However,
the limited material availability makes these studies more
relevant in basic science but not in routine clinical practice.
In our previous publications, we described the comparison
between abundances of all plasma proteins and differences at
the transcriptional level (mRNA) from prematurely born
children with different gestational ages, both from cord blood
as well as at the 36th postmenstrual week (36 PMA).13–15 We
presented that protein abundance differences are highly
dependent on gestation age.
The goal of this study was to identify potential ROP plasma
biomarkers and provide a more molecular-based understanding
of ROP by comparing a proteome profile at the two time points
(at birth and at 36 PMA) in groups of infants with and without
ROP. However, as our previous studies revealed, the level of
Copyright 2018 The Authors
iovs.arvojournals.org j ISSN: 1552-5783 5312
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Downloaded from iovs.arvojournals.org on 10/13/2020
prematurity has a profound impact on the plasma protein
quantitative changes. Therefore, we performed a standardiza-
tion of the obtained results to the gestational age. Our
secondary aim was to corroborate the protein level by a
complementary gene expression study.
METHODS
This study is an analysis of data collected as part of a multisite
study to investigate the transcriptome and proteome in
preterm infants.13–15 The study was approved by the Jagiello-
nian University Bioethical Committee and adheres to the tenets
of the Declaration of Helsinki.
Enrolled Patients
All preterm newborns with a gestational age of 30 weeks
were consecutively enrolled into the study between September
1, 2013, and November 30, 2015, at the Warsaw Medical
University Neonatal Intensive Care Unit (NICU), Warsaw,
Poland. Informed consent was obtained antenatally from the
parents with an explanation of the nature and possible
consequences of the study.
Monitoring During Hospitalization
All the subjects enrolled in the study underwent careful clinical
monitoring for symptoms of ROP, as the standard of care. The
screening of infants for ROP followed standard guidelines.16
The examination and the qualification for laser therapy were
provided by an experienced specialist in ophthalmology and
retina diseases. Laser photocoagulation was performed on
children who developed any stage ROP with plus disease in
zone I, stage 3 ROP without plus disease in zone I, or stage 2 or
3 ROP with plus disease in zone II. In the case of ROP
progression despite laser treatment, the patient might have
been qualified to receive anti-vascular endothelial growth
factor therapy.
Data Collection
Data concerning perinatal history, hospitalization course, and
the patient’s outcome, with special regard to the course and
treatment of ROP, were simultaneously collected in an Excel
database.
Division Into Groups
All patients with eye changes typical for any stage of ROP17
were included into the ROP(þ) group. Patients without any eye
abnormalities associated with ROP formed the ROP() group.
Blood Sampling
Blood samples for transcriptome and proteome analyses were
collected at two time points: during delivery (umbilical cord
blood) and at 36 PMA peripheral venous blood. The blood
samples were further managed as previously described in detail
elsewhere.13–15
Proteome Analysis
ProteoMiner beads (combinatorial peptide ligand library beads;
Bio-Rad, Hercules, CA, USA) were used for the enrichment
procedure, optimized with reference to previously published
protocols.18,19 The quantitative analysis was performed by
isobaric tag for a relative and absolute quantitation (iTRAQ)
method (Sciex, Framingham, MA, USA). Samples were en-
riched, trypsin-digested, randomly assigned to iTRAQ reagents,
labeled, and, finally, combined to corresponding 8plex
assemblies. For data normalization, each 8plex assembly
contained an internal common reference generated by
combining equal amounts of protein from all of the samples
included in the measurements. Next, labeled peptides were
fractionated by strong cation exchange chromatography, after
which flow-through fraction and 11 consecutive injections of
the elution buffer (5–500 mM ammonium acetate) were
collected. Thus, the labeled peptides from each 8plex assembly
were distributed across 12 strong cation exchange fractions.
Each fraction was then separated by reversed-phase liquid
chromatography and applied on-line to a Velos Pro (Thermo
Scientific, Waltham, MA, USA) mass spectrometer through a
nanoelectrospray ion source. Spectra were collected in full
scan mode (400–1500 Da), followed by five pairs of collisional-
induced dissociation (CID) and higher energy collisional
dissociation (HCD) tandem mass spectrometry (MS/MS) scans
of the five most intense precursor ions from the survey full
scan and, subsequently, merged to hybrid HCD-CID spectra by
EasierMGF software.20 These were analyzed by the X!Tandem
(The GPM Organization)21 and Comet22 search engines,
statistically validated with PeptideProphet, and integrated with
iProphet23 under the Trans-Proteomic Pipeline (TPP) suite of
software (Institute for Systems Biology, Seattle, WA, USA).24
The peptide false discovery rate (FDR) was estimated by
Mayu25 (TPP), and peptide identifications with an FDR below
1% were considered to be correct matches. Imputation of the
missing values in peptide abundances was performed in a
MaxQuant environment26 on the log2-transformed normalized
iTRAQ, which reports intensities with a criterion of at least
75% of the values present for a peptide in the dataset by
drawing the values from the normal distribution, with
parameters optimized to mimic a typical low-abundance
measurement. DanteR software27 was used for protein
quantitation and the statistical analysis of iTRAQ-labeled
peptides. ANOVA was performed at the peptide level by using
a linear model with the Benjamini and Hochberg FDR
correction used to adjust P values. Protein fold change was
reported as a median value of corresponding unique peptides.
Justification of Sample Size
A formal sample size calculation was not performed so as to
allow the realization of a hypothesis-generating study. The
approximate sample size was based on the calculations for the
main study.13 Briefly, the basic goal of the main project was to
compare protein abundance levels between groups with a
different degree of maturity. The power analysis (http://www.
dssresearch.com/toolkit/default.asp; provided in the public
domain by DSS Research, Fort Worth, TX, USA) indicated that
with n ¼ 19 patients in each preterm group, the estimated
power of the study to validate the measured fold change at the
level of 1.15 was 0.98 (P ¼ 0.05). Therefore, n ¼ 19 patients
were enrolled to each preterm subgroup. Using the calculation
mentioned above, we can state that the power of this study is
at least that in the publication mentioned above; we can detect
at least a 1.15-fold change in protein abundance between
ROP() and ROP(þ) patients.
Microarray Analysis
To study the whole-genome expression with a comprehensive
coverage of proteins by appropriate gene transcripts, SurePrint
G3 Human Gene Expression v3, 8 3 60 K microarrays (Agilent,
Santa Clara, CA, USA) were used. A detailed methodology of
handling the samples was described previously.15 A microarray
gene expression experiment was performed according to the
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manufacturer’s protocol (Two-Color Microarray-Based Gene
Expression Analysis, Low Input Quick Amp Labeling v6.9.1).
After the experiment, the arrays were scanned by the SureScan
Microarray Scanner (Agilent) and data were extracted using the
Feature Extraction Software (Agilent). The expression of
selected genes was confirmed by RT-PCR analysis as described
in detail elsewhere.15
Statistical Analysis
Descriptive statistics were calculated and compared across the
groups using Student’s t-tests or Fisher exact tests for variables
such as gestational age and birthweight, sex, antenatal steroids,
and selected neonatal complications, including chorioamnio-
nitis and oxygen therapy at the 28th day of life and 36 weeks
PMA. A Mann-Whitney U test was used to compare the length
of oxygen therapy between the groups. The groups deter-
mined by the comparison of interest were not comparable
with respect to gestational age. Therefore, we wanted to
examine whether differences in protein concentrations be-
tween the groups were due to gestational age. A linear model
was fitted to the protein concentrations for each protein, and
Student’s t-tests and F-statistics were computed for each
contrast, group indicator and gestational age. For each protein
that was found to have a different concentration between the
groups (i.e., that had a FDR-adjusted P value <0.05 in the first
part of the analysis), we tested whether this expression was
explained by the group indicator and/or by gestational age,
using a logistic regression analysis. For statistical analysis, an
SPSS software package (IBM SPSS Statistics for iOS, v24.0; IBM
Corp., Armonk, NY, USA) was used.
RESULTS
Fifty-seven preterm newborns were included in the study, and,
with two time points of blood drawing, this resulted in the
collection of a total of 114 samples for proteomic and
transcriptomic analysis. During their hospitalization in the
NICU, 28 infants who had developed ROP formed the ROP(þ)
group and 29 ROP-negative infants formed the second group
(Fig.). The overall characteristics of the cohort and the
differences in selected variables across the analyzed groups
are shown in Table 1. Children who, during hospitalization,
developed ROP were characterized by a lower gestational age
and birthweight, and, moreover, they required more prolonged
oxygen therapy.
In the first stage of the analysis, the concentrations of
proteins in serum obtained from the cord blood of preterm
born children were analyzed. The abundance level of 33 of the
proteins for the group who, during hospitalization, developed
ROP were significantly different when compared with preterm
infants who did not have this complication (Table 2). The
quantitative comparisons between samples collected at 36
weeks PMA from ROP(þ) and ROP() groups revealed a
significantly different abundance level of 30 proteins (Table 3).
After adjustment for gestational age, complement C3 and
fibrinogen alpha chain revealed a significant association with
ROP at both time points. Moreover, at 36 PMA, the fibrinogen
gamma chain revealed a significant, and the fibrinogen beta
chain a borderline, association with ROP (Tables 2 and 3).
Among the 28 children with ROP, 5 presented ROP at the stage
which required laser photocoagulation. This subgroup gener-
ally consisted of the most immature infants: gestational age,
24.6 (SD 1.94) weeks; birthweight, 750 (SD 176) grams; female
sex, 3 (60%); prenatal steroids, 3 (60%); sepsis, 1 (20%);
intraventricular hemorrhage grade 3/4, 1 (20%); on oxygen at
28th day of life, 5 (100%); on oxygen at 36 weeks PMA, 2
(40%); clinical chorioamnionitis, 3 (60%); histologic chorioam-
nionitis, 3 (60%). No one required antivascular endothelial
growth factor therapy. In order to broaden the spectrum of
observed changes to different biological level of regulation, the
obtained results were compared in detail with the results of the
gene expression microarray study. At both analyzed time
points, significant differences for complement C3 component
were observed (Table 4).
DISCUSSION
Our study presents the results of plasma proteome analysis in
infants who, after birth at 30 gestational weeks, subsequently
developed or did not develop ROP. Our findings support
previous literature by showing that lower gestational age and
birth weight correlate with a higher risk of developing ROP
during hospitalization. Moreover, ROP(þ) and ROP() groups
differed in the length of oxygen therapy as well as the
proportion of children who developed bronchopulmonary
dysplasia, which is also an oxygen-use-connected disease.
Therefore, we consider oxygen therapy as the most significant
predictor of ROP. Moreover, we identified two proteins whose
increased level in cord blood plasma differentiate children with
and without the risk of subsequently developing ROP.
Additionally, these differences were also present in the
examination of blood plasma obtained from the same infants
TABLE 1. Comparison of Selected Demographic Variables and Hospitalization Data of the Patients in the Studied Groups
Variables ROP() Group, n ¼ 29 ROP(þ) Group§, n ¼ 28 P Value
Gestational age in weeks, mean (SD) 28 (1) 26 (2) <0.001*
Birthweight in g, mean (SD) 1097 (245) 904 (220) 0.003*
Female sex† 18 (62.1) 20 (71.4) 0.576‡
Antenatal steroids† 23 (79.3) 21 (75) 0.760‡
Clinical signs of chorioamnionitis† 7 (25) 14 (50) 0.097‡
Histologically confirmed chorioamnionitis† 7 (26.9) 14 (53.8) 0.089‡
Sepsis† 1 (3.5) 2 (7.1) 0.612‡
Intraventricular hemorrhage grade 3/4† 0 (0) 2 (7.1) 0.237‡
Oxygen therapy in days, mean (IQR) 11 (2–38) 51 (32–71) <0.001§
On oxygen during 28th day of life† 12 (41.4) 24 (85.7) 0.001‡
On oxygen at 36 weeks postmenstrual age (PMA)† 1 (3.4) 6 (21.4) 0.052‡
* Student’s t-test.
† Results are presented as n (%).
‡ Fisher’s exact test.
§ Mann-Whitney U test.
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at 36 PMA, elucidating the proteomic profile that predisposes a
child to ROP.
Complement is an important component of the innate
immune system, crucial for defense against microbial infec-
tions and for clearance of immune complexes and injured cells.
Under normal conditions, its activation is tightly controlled and
relies on pathogen-binding antibodies (classical pathway and
lectin pathway), apart from low-level continuous activation
caused by spontaneous C3 hydrolysis (alternative pathway).28
When hyper-activated, it drives a severe inflammatory
response in numerous organs. Complement C3 is a central
component of the complement cascade. Overactivation of the
complement cascade has been implicated in the disease
progression of glaucoma and diabetic retinopathy and is now
known to be a central driver in the pathogenesis of age-related
macular degeneration (AMD).29,30 Complement C1 and C3
elevation in the plasma have been reported as diabetic
retinopathy markers.31 In a quantitative proteomic analysis
using iTRAQ of murine retina with oxygen-induced retinopathy
versus healthy retinas, performed by Zhou et al.,32 higher levels
FIGURE. Flowchart showing samples included in the iTRAQ analysis.
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of C3 and C4 were found in murine retinopathic retinas. It is
possible that complement was deposited in retinas after
breaking the blood-retinal barrier, as a consequence of retinal
hemorrhage.32 Of note, the vitreous of diabetic patients with
proliferative retinopathy also contains more complement
factors than patients without retinopathy or with nonprolifer-
ative retinopathy. This observation is also explained by
researchers as a breakage of a blood-retinal barrier33; however,
the level of plasma complement in these patients was not
checked. Rathi et al.34 showed an increased level of C3 (and
also C4 complement component) in the vitreous and tear
samples of babies with ROP in comparison with infants with
congenital cataract. This study indicated a possible involve-
ment of the alternative complement pathway in ROP.
According to the authors, the intraocular complement cascade
activates macrophages/microglia, which secretes proangiogen-
ic proteins and diminishes angiogenesis inhibitor levels. That
may lead to increased vessel proliferation and extracellular
matrix degeneration, in turn promoting angiogenesis.34 On the
contrary, in a study by Langer et al.35 of a murine model of ROP,
mice deficient in a C3 complement component displayed
increased neovascularization; moreover, an antibody-mediated
blockade of other complement factors resulted in enhanced
pathological retinal angiogenesis.35 Our study adds further
evidence to the relationship between elevated complement
levels and the development of one of the ischemic retinopa-
thies, which is ROP. However, the exact connection has to be
established in a targeted study. It is possible that chronic
inflammatory abnormalities occurring in premature infants,
caused by infections or prolonged oxygen use and excessive
free radical formation, or even in the absence of well-defined
triggers, may be reflected by an increased plasma C3
complement component level.
Fibrinogen is a 340-kD plasma protein synthesized by
hepatocytes and is essential for blood coagulation. It is
composed of two sets of three subunits, alpha, beta, and
gamma. Under physiologic conditions, fibrinogen is found in
plasma at low levels. However, after injury or endothelial cell
dysfunction and/or vessel leakage, fibrinogen levels increase in
the plasma. Fibrinogen is also a pleiotropic signaling molecule
with numerous roles that can tip the balance between
hemostasis and thrombosis and coagulation and fibrosis.
Fibrinogen has also been shown to play a central role in
inflammation.36 Growing evidence indicates that perinatal
inflammation and infection may increase the risk of ROP by
direct proangiogenic effects and/or modifying known risk
factors.37–41 According to Christensen et al.,42 increased
fibrinogen levels may be associated with in utero infection/
inflammation. On the contrary, Mitra et al.43 stated in their
meta-analysis that chorioamnionitis cannot be definitively
considered as a risk factor for ROP. In our study, the difference
in frequency of chorioamnionitis in each group, assessed both
TABLE 2. Baseline Differences in Cord Blood Plasma Proteome Among Infants Who Developed ROP vs. Those Who Did Not
UniProt Protein Name
UniProt
Accession No. Ratio
P for Multiple
Comparisons
Ratio
Adjusted
for GA
P Adjusted
for GA and
Multiple
Comparisons
Alpha-1-antichymotrypsin P01011 1.1862517 0.000280595 1.050 ns
Alpha-2-antiplasmin P08697 1.1100158 0.005351421 1.047 ns
Alpha-2-macroglobulin P01023 0.918113 8.59E05 1.097 ns
Alpha-fetoprotein P02771 1.0875556 0.006899515 1.251 ns
Apolipoprotein A-I P02647 0.9224167 0.000826357 0.898 ns
Apolipoprotein A-II P02652 0.8708346 0.043272716 0.990 ns
Apolipoprotein A-IV P06727 0.8715872 1.84E07 0.963 ns
Apolipoprotein D P05090 0.9141908 0.020824291 0.977 ns
Apolipoprotein E P02649 1.1210865 0.019551286 1.178 ns
Carboxypeptidase N subunit 2 P22792 0.9143531 0.030350218 0.829 ns
Clusterin P10909 1.0736791 0.043818022 1.009 ns
Coagulation factor X P00742 1.1286653 0.046620218 1.171 ns
Complement C3 P01024 1.0935421 1.99E06 1.270 0.001
Corticosteroid-binding globulin P08185 1.1215194 0.008725224 1.050 ns
Fibrinogen alpha chain P02671 1.0704448 0.014554203 1.246 0.001
Gelsolin P06396 0.943472 0.046168199 0.853 ns
Haptoglobin P00738 1.3988051 9.71E05 1.216 ns
Hemoglobin subunit beta P68871 0.8777652 0.02075909 0.793 ns
Hemopexin P02790 1.2818429 1.67E08 1.103 ns
Hyaluronan-binding protein 2 Q14520 1.1208541 0.048320148 1.034 ns
Immunoglobulin heavy constant gamma 1 P01857 0.809804 0.000197058 0.766 ns
Immunoglobulin heavy constant gamma 2 P01859 0.847571 0.015480447 0.722 ns
Immunoglobulin heavy constant gamma 3 P01860 0.8532499 0.000465464 0.905 ns
Immunoglobulin kappa constant P01834 0.8879205 0.025928432 0.890 ns
Immunoglobulin lambda-like polypeptide 5 B9A064 0.841204 0.000385047 0.740 ns
Inter-alpha-trypsin inhibitor heavy chain H4 Q14624 1.1757714 0.00022227 1.093 ns
Lumican P51884 0.9033466 0.000652683 0.959 ns
Phosphatidylcholine-sterol acyltransferase P04180 1.2675799 0.000599877 1.155 ns
Pigment epithelium-derived factor P36955 0.9346042 0.026092851 0.798 ns
Serotransferrin P02787 0.8758036 4.86E08 0.934 ns
Serum paraoxonase/arylesterase 1 P27169 0.8855303 0.034710754 0.917 ns
Vitronectin P04004 1.1049064 0.004711251 0.978 ns
GA, gestational age; ns, not significant.
Proteomic Analysis of Plasma Proteins in Newborns With ROP IOVS j November 2018 j Vol. 59 j No. 13 j 5316
Downloaded from iovs.arvojournals.org on 10/13/2020
clinically and histologically, did not reach the statistical
significance; therefore, we cannot regard intrauterine infection
as the only reason for the elevated level of fibrinogen.
In a murine model of ROP, fibrinogen deposits were seen in
retinas, indicating an incompetent blood-retinal barrier and a
leak of this big molecule from the blood into the retina,
suggesting an inflammatory response inside of the eye.44 Of
note, an elevated level of fibrinogen was demonstrated as a risk
factor in other non-ROP ischemic retinopathies, such as
diabetic retinopathy and AMD. An increased plasma fibrinogen
level is an independent factor associated with the existence of
diabetic retinopathy. Coagulation and fibrinolysis disturbances
are significantly associated with diabetic retinopathy and exist
at the early stage of microangiopathy.45–47 An increased level of
fibrinogen alpha chain in the vitreous was observed in patients
with exudative AMD.48 A higher plasma fibrinogen level was
also observed in patients with AMD.49 Until now, higher
plasma fibrinogen levels were not directly linked with a higher
risk of developing ROP. Based on the results of our study, we
believe that it is worth researching this issue in more detail.
To independently confirm iTRAQ results at a different
regulatory level (RNA) with the proteome results, we also
compared the expression of RNA in peripheral blood
mononuclear cells (PBMCs) for the C3 complement compo-
nent. It turned out that it is consistent with the results of the
proteome analysis, that is it is higher in PBMCs from ROP(þ)
children. As the gene for the C3 complement component is
expressed to some extent in the PBMCs,50 it can conceivably
be presumed that PBMCs may have some minor contribution
to increased plasma C3 concentration. However, for fibrino-
gen, our microarray results do not confirm the results obtained
in the proteome study. It may be connected with the fact that
the main source of fibrinogen is the liver and the proportion of
fibrinogen expression in leukocytes and liver is 9:>1000000.51
Therefore, the expression of fibrinogen in PBMCs does not
reflect its plasma concentration. But, taking into consideration
TABLE 3. Differences in Plasma Proteome Among Infants Who Developed ROP vs. Those Who Did Not*
UniProt Protein Name
UniProt
Accession No. Ratio
P for Multiple
Comparisons
Ratio
Adjusted
for GA
P Adjusted
for GA and
Multiple
Comparisons
Actin, alpha cardiac muscle 1 P68032 1.1906644 0.0475514 1.056 ns
Afamin P43652 1.0799864 0.0315553 1.123 ns
Alpha-1-antichymotrypsin P01011 0.907247 0.036339 0.917 ns
Alpha-1-antitrypsin P01009 0.9434103 0.0286758 1.055 ns
Alpha-2-macroglobulin P01023 1.06327 0.0044039 1.12 ns
Alpha-fetoprotein P02771 1.170529 2.37E-05 1.17 ns
Antithrombin-III P01008 1.1046542 0.0403643 1.085 ns
Apolipoprotein C-II P02655 0.8994437 0.0066565 0.926 ns
Apolipoprotein D P05090 0.9043838 0.0070745 0.922 ns
CD44 antigen P16070 0.9067142 0.0468983 1.018 ns
Clusterin P10909 1.1138118 0.0026749 1.146 ns
Complement C3 P01024 1.0535554 0.0092711 1.294 0.01
Corticosteroid-binding globulin P08185 1.1463512 0.0018683 1.193 ns
Fibrinogen alpha chain P02671 1.1117484 6.27E-05 1.304 0.001
Fibrinogen beta chain P02675 1.0837173 0.0042849 1.196 0.05
Fibrinogen gamma chain P02679 1.1369312 0.0001472 1.209 0.01
Hemopexin P02790 0.9106301 0.0261357 1.02 ns
Immunoglobulin heavy constant gamma 1 P01857 0.8770847 0.0416061 1.118 ns
Immunoglobulin kappa constant P01834 0.8573033 0.0087608 0.992 ns
Immunoglobulin lambda-like polypeptide 5 B9A064 0.8269632 0.0004377 0.978 ns
Inter-alpha-trypsin inhibitor heavy chain H2 P19823 0.9218176 0.0006118 1.031 ns
Inter-alpha-trypsin inhibitor heavy chain H3 Q06033 0.9196707 0.0127338 0.986 ns
L-selectin P14151 0.8711616 0.0025764 0.991 ns
Leucine-rich alpha-2-glycoprotein P02750 0.828691 7.82E-05 0.782 ns
Lumican P51884 0.8680893 5.75E-07 0.914 ns
Osteopontin P10451 0.882484 0.0363684 0.998 ns
Phosphatidylcholine-sterol acyltransferase P04180 1.1502718 0.0415306 1.151 ns
Plasma protease C1 inhibitor P05155 0.905963 0.0002958 0.992 ns
Prothrombin P00734 1.0878711 0.0039182 1.204 ns
Zinc-alpha-2-glycoprotein P25311 1.0855388 0.0113501 1.145 ns
GA, gestational age; ns, not significant.
* Assessed at 36 PMA.
TABLE 4. Analysis of the Expression of Fibrinogen Alpha and C3 Complement Component Genes
Gene
Cord Blood, n ¼ 57 36 PMA Peripheral Venous Blood, n ¼ 57
Fold Change ROP(þ) vs. ROP() P Fold Change ROP(þ) vs. ROP() P
fibrinogen alpha chain 1.062 0.38 0.969 0.54
complement component 3 1.100 0.013 1.087 0.032
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the results of the studies by Hoppe and colleagues,52,53 we
believe that it may be possible in the future to investigate
targeted therapy to reduce the production of fibrinogen in the
liver, which may act in a protective way on retinal capillary
beds.
Limitations
The specific characteristics of the studied population might
have influenced the results that were obtained; namely, that
they were biased toward a statistically significant difference.
The patient population may not be applicable to other NICUs
(for example, the ROP rate), and, hence, our results may not be
easily generalizable. Moreover, due to the nature of our study,
there may be a potential collider bias in controlling for
gestational age when low gestational age is highly associated
with preterm birth, which is linked with ROP and potentially
pathophysiologic factors. These issues are difficult, and
sometimes unavoidable, in observational studies that are
necessary when studying prematurely born children. Addition-
ally, the validation of proteomic results by another method
would strengthen the iTRAQ quantitation results. It has to be
stated, however, that the sample consuming the ProteoMiner
plasma enrichment allowed us only to meet the requirements
for reliable iTRAQ measurements. In addition, the extensive
fractionation of the labeled peptides by off-line two-dimen-
sional chromatography and mass spectrometry provided the
sensitivity of the plasma proteins analysis that would probably
not be reached by the Western blot technique, which is still
considered to be the standard method for targeted protein
quantitation.
CONCLUSIONS
To sum up, higher levels of complement C3 component and
fibrinogen present in the cord blood that persistent to 36 PMA
may indicate a chronic low-grade systemic inflammation and
hypercoagulable state, which may play a role in the develop-
ment of ROP.
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